PANACEABIO.NS NSE

Established in 1984 and headquartered in New Delhi, India, Panacea Biotec Limited is a biotechnology company dedicated to the innovation, production, and commercialization of pharmaceuticals, vaccines, and biosimilars. Its primary market is India, with operations segmented into Vaccines and Formulations. The company's pharmaceutical offerings comprise proprietary medicines targeting diverse medical fields such as pain management, diabetes, cardiovascular health, oncology, renal disease, osteoporosis, anti-tubercular therapy, and gastro-intestinal care. In addition to these, Panacea Biotec develops and distributes vaccines for conditions like anthrax, dengue, and Japanese encephalitis, among others. The firm maintains a robust global presence, exporting its goods to over 30 countries, including key markets such as the United States, Germany, the Russian Federation, Sri Lanka, and the Philippines. Notably, Panacea Biotec has established significant strategic alliances, including a partnership with the Russian Direct Investment Fund for the manufacture of the Sputnik-V COVID-19 vaccine. It also collaborates with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Translational Health Science and Technology Institute (THSTI) to pioneer vaccine candidates designed to combat SARS-CoV-2 variants and other beta coronaviruses.